Advanced search
1 file | 1.77 MB Add to list

Biologic therapies for severe asthma

(2022) NEW ENGLAND JOURNAL OF MEDICINE. 386(2). p.157-171
Author
Organization
Abstract
Biologic Therapies for Severe Asthma Patients with severe asthma are at increased risk for a decreased quality of life, fixed airway obstruction, hospitalization, and death. Biologics may be required to reduce the disease burden. This review discusses the mechanisms, efficacy, and safety of biologics for severe asthma.
Keywords
SEVERE EOSINOPHILIC ASTHMA, QUALITY-OF-LIFE, DOUBLE-BLIND, MONOCLONAL-ANTIBODY, PRECISION MEDICINE, NASAL POLYPOSIS, MEPOLIZUMAB, PLACEBO, BENRALIZUMAB, EFFICACY

Downloads

  • (...).pdf
    • full text (Published version)
    • |
    • UGent only (changes to open access on 2022-07-14)
    • |
    • PDF
    • |
    • 1.77 MB

Citation

Please use this url to cite or link to this publication:

MLA
Brusselle, Guy, and Gerard H. Koppelman. “Biologic Therapies for Severe Asthma.” NEW ENGLAND JOURNAL OF MEDICINE, vol. 386, no. 2, 2022, pp. 157–71, doi:10.1056/NEJMra2032506.
APA
Brusselle, G., & Koppelman, G. H. (2022). Biologic therapies for severe asthma. NEW ENGLAND JOURNAL OF MEDICINE, 386(2), 157–171. https://doi.org/10.1056/NEJMra2032506
Chicago author-date
Brusselle, Guy, and Gerard H. Koppelman. 2022. “Biologic Therapies for Severe Asthma.” NEW ENGLAND JOURNAL OF MEDICINE 386 (2): 157–71. https://doi.org/10.1056/NEJMra2032506.
Chicago author-date (all authors)
Brusselle, Guy, and Gerard H. Koppelman. 2022. “Biologic Therapies for Severe Asthma.” NEW ENGLAND JOURNAL OF MEDICINE 386 (2): 157–171. doi:10.1056/NEJMra2032506.
Vancouver
1.
Brusselle G, Koppelman GH. Biologic therapies for severe asthma. NEW ENGLAND JOURNAL OF MEDICINE. 2022;386(2):157–71.
IEEE
[1]
G. Brusselle and G. H. Koppelman, “Biologic therapies for severe asthma,” NEW ENGLAND JOURNAL OF MEDICINE, vol. 386, no. 2, pp. 157–171, 2022.
@article{8744130,
  abstract     = {{Biologic Therapies for Severe Asthma Patients with severe asthma are at increased risk for a decreased quality of life, fixed airway obstruction, hospitalization, and death. Biologics may be required to reduce the disease burden. This review discusses the mechanisms, efficacy, and safety of biologics for severe asthma.}},
  author       = {{Brusselle, Guy and Koppelman, Gerard H.}},
  issn         = {{0028-4793}},
  journal      = {{NEW ENGLAND JOURNAL OF MEDICINE}},
  keywords     = {{SEVERE EOSINOPHILIC ASTHMA,QUALITY-OF-LIFE,DOUBLE-BLIND,MONOCLONAL-ANTIBODY,PRECISION MEDICINE,NASAL POLYPOSIS,MEPOLIZUMAB,PLACEBO,BENRALIZUMAB,EFFICACY}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{157--171}},
  title        = {{Biologic therapies for severe asthma}},
  url          = {{http://dx.doi.org/10.1056/NEJMra2032506}},
  volume       = {{386}},
  year         = {{2022}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: